FibroGenesis Announces the Filing of its 200th Patent for Fibroblast Cell Therapy Platform

Building on a World Leading Intellectual Property Position with the 200th Patent Filed Today

News provided by

FibroGenesis

21 Apr, 2020, 09:13 ET

HOUSTON, April 21, 2020 /PRNewswire/ -- FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced the filing of its 200th patent related to its fibroblast cell therapy platform.

Continue Reading
Fibroblast Cells
Fibroblast Cells

Building on its world leading position as the authority on using fibroblasts to treat chronic diseases, FibroGenesis expands its worldwide intellectual property covering chronic diseases such as COVID-19 ARDS, Degenerative Disc Disease, Multiple Sclerosis, Diabetes, Cancer, Chronic Traumatic Encephalopathy (CTE), Pain and Muscular Dystrophy.

"I'm proud to enter the lab every day to create new opportunities for this "super cell," commented Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis.  "Internal data, along with third party validation, shows our proprietary universal donor fibroblast-based product outperforms exiting approaches.  The broad potential of this novel therapy and the broad intellectual property establishes FibroGenesis as the gatekeeper for anyone entering this space."

"We are excited to continuing building our intellectual property surrounding this emerging technology," said Pete O'Heeron, Chief Executive Officer, FibroGenesis.  "Expanding our world leading position in fibroblast cell therapy, our proprietary platform continues to find a uniquely potent position among emerging cell therapies."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 186 U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit www.Fibro-Genesis.com.

SOURCE FibroGenesis

Related Links

https://www.fibro-genesis.com/

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.